Timothy W. Neal* and John R. Zuniga
Patients treated with opioids for the management of acute pain often experience opioid induced nausea and vomiting (OINV). OINV compromises pain control, leads to sleep disturbances, and increase in health care costs. Currently, there is no approved therapeutic agent to treat acute pain while preventing and reducing OINV. This has led to the production of Hydexor (CL-108), which is a combination agent containing opioid and an antiemetic. The purpose of this review is to revisit the use of CL-108 as a modality in the reduction of OINV, and to provide an update for use.
Published Date: 2021-07-22; Received Date: 2021-07-01